secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001683168-24-006281
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma regains Nasdaq bid-price compliance; faces 1-year monitoring with strict delisting risk
--------------------------------------------------------------------------------

- Received Nasdaq letter confirming compliance with Bid Price Rule (Listing Rule 5550(a)(2)).
- Subject to Mandatory Panel Monitor for one year from September 9, 2024.
- If non-compliant during monitoring, no cure period allowed; Nasdaq will issue Delist Determination Letter.
- Company may request a new hearing if delist determination is issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824006281/0001683168-24-006281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824006281/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-006281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer